Firalis Molecular Precision

France's Leading NGS Service-Provider with Illumina's Cutting-Edge sequencing technologies

Firalis Molecular Precision has emerged as France’s leading NGS service-provider, spearheading the genomics revolution in the country.

With a steadfast commitment to excellence, innovation, and precision, Firalis Molecular Precision has acquired Illumina’s groundbreaking sequencing technologies, including the NextSeq 500, NextSeq 2000, NovaSeq 6000 Dx, and the highly anticipated Novaseq X-Plus.

These technologies represent the pinnacle of genomics technology and enable Firalis Molecular Precision to deliver unparalleled precision, scalability, and efficiency to its esteemed clientele.

  • NextSeq 500: The NextSeq 500 offers exceptional flexibility and high-throughput capabilities, making it a powerful tool for a wide range of genomic applications. With rapid turnaround times and high-quality data output, this platform empowers researchers to delve deeper into the complexities of the genome, unlocking new insights and accelerating scientific discoveries.
  • NextSeq 2000: Building upon the success of its predecessor, the NextSeq 2000 represents a significant advancement in NGS technology. Offering increased sequencing capacity and enhanced data output, this platform enables Firalis Molecular Precision to undertake large-scale genomics projects with ease. Researchers benefit from reliable and accurate results, driving breakthroughs in diverse fields, including cancer genomics, rare disease research, and pharmacogenomics.
  • NovaSeq 6000 Dx: The acquisition of the NovaSeq 6000 Dx underscores Firalis Molecular Precision’s commitment to precision diagnostics. This platform, specifically designed for clinical diagnostics, ensures the highest standards of accuracy and reliability. It empowers healthcare professionals with the tools they need to deliver personalized medicine, enabling early disease detection, optimized treatment strategies, and improved patient outcomes.
  • Novaseq X-Plus (upcoming): Anticipation surrounds the forthcoming acquisition of the Novaseq X-Plus by Firalis Molecular Precision. This state-of-the-art platform promises enhanced sequencing capabilities, longer read lengths, and improved accuracy. 

Share on your socials!